HUP0302451A2 - (Tio)karbamoil-ciklohexán származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények - Google Patents

(Tio)karbamoil-ciklohexán származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0302451A2
HUP0302451A2 HU0302451A HUP0302451A HUP0302451A2 HU P0302451 A2 HUP0302451 A2 HU P0302451A2 HU 0302451 A HU0302451 A HU 0302451A HU P0302451 A HUP0302451 A HU P0302451A HU P0302451 A2 HUP0302451 A2 HU P0302451A2
Authority
HU
Hungary
Prior art keywords
group
carbamoyl
thio
producing
pharmaceutical compositions
Prior art date
Application number
HU0302451A
Other languages
English (en)
Inventor
Csongor Éva Ágainé
János Galambos
Katalin Nógrádi
István Vágó
István Gyertyán
Béla Kiss
István Laszlovszky
Judit Laszy
Katalin Sághy
Original Assignee
Richter Gedeon Vegyészeti Gyár Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0302451A priority Critical patent/HU227534B1/hu
Application filed by Richter Gedeon Vegyészeti Gyár Rt. filed Critical Richter Gedeon Vegyészeti Gyár Rt.
Publication of HU0302451D0 publication Critical patent/HU0302451D0/hu
Priority to RS20060041A priority patent/RS52771B/en
Priority to PCT/HU2004/000056 priority patent/WO2005012266A1/en
Priority to EP04734301A priority patent/EP1663996B1/en
Priority to SI200431919T priority patent/SI1663996T1/sl
Priority to AU2004261490A priority patent/AU2004261490B2/en
Priority to CA002532818A priority patent/CA2532818C/en
Priority to PT04734301T priority patent/PT1663996E/pt
Priority to MXPA06001033A priority patent/MXPA06001033A/es
Priority to MEP-2008-849A priority patent/ME00564B/me
Priority to UAA200600942A priority patent/UA84022C2/ru
Priority to PL04734301T priority patent/PL1663996T3/pl
Priority to KR1020067002364A priority patent/KR100870284B1/ko
Priority to ES04734301T priority patent/ES2389840T3/es
Priority to BRPI0413283A priority patent/BRPI0413283B8/pt
Priority to JP2006522421A priority patent/JP3999806B2/ja
Priority to CN2004800219507A priority patent/CN1829703B/zh
Priority to DK04734301.7T priority patent/DK1663996T3/da
Priority to NZ544999A priority patent/NZ544999A/en
Priority to EA200600364A priority patent/EA009022B1/ru
Priority to TW093115688A priority patent/TWI327141B/zh
Priority to MYPI20042187A priority patent/MY142760A/en
Publication of HUP0302451A2 publication Critical patent/HUP0302451A2/hu
Priority to IL172746A priority patent/IL172746A/en
Priority to IS8199A priority patent/IS2905B/is
Priority to TNP2005000328A priority patent/TNSN05328A1/en
Priority to US11/337,275 priority patent/US7737142B2/en
Priority to ZA200601026A priority patent/ZA200601026B/en
Priority to MA28855A priority patent/MA28024A1/fr
Priority to NO20061076A priority patent/NO334973B1/no
Priority to HK07100087.7A priority patent/HK1093494A1/xx
Priority to US12/779,014 priority patent/US20100240640A1/en
Publication of HU227534B1 publication Critical patent/HU227534B1/hu
Priority to HRP20120715TT priority patent/HRP20120715T1/hr
Priority to CY20121100815T priority patent/CY1113099T1/el
Priority to LTPA2017027C priority patent/LTC1663996I2/lt
Priority to NO2017051C priority patent/NO2017051I2/no
Priority to FR17C0008C priority patent/FR17C0008I1/fr
Priority to LU00039C priority patent/LUC00039I2/en
Priority to CY2017032C priority patent/CY2017032I2/el
Priority to HUS1700044C priority patent/HUS1700044I1/hu
Priority to BE2017C045C priority patent/BE2017C045I2/fr
Priority to NL300913C priority patent/NL300913I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A találmány tárgya új (I) általános képletű a D3 és D2 dopaminreceptor altípusokat előnyben részesítő ligandumok - melyek képletébenR1 és R2 jelentése egymástól függetlenül hidrogénatom, alkilcsoport,arilcsoport, alkenilcsoport, cikloalkilcsoport, aroilcsoport, vagy R1és R2 a közbezárt nitrogénatommal együtt heterociklikus csoportotképezhet; X jelentése oxigénatom vagy kénatom; n értéke 1 vagy 2 -,és/vagy geometriai izomerjeik és/vagy sztereoizomerjeik és/vagydiasztereomerjeik és/vagy sóik és/vagy hidrátjaik és/vagy szolvátjaik,ezek előállítási eljárásai, ezeket tartalmazó gyógyászatikészítmények, és alkalmazásuk olyan kóros állapotok kezelésében,illetve kialakulásának megelőzésében, amelyek dopamin receptorokmodulálását kívánják. Ó
HU0302451A 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them HU227534B1 (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EA200600364A EA009022B1 (ru) 2003-08-04 2004-05-21 Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
MXPA06001033A MXPA06001033A (es) 2003-08-04 2004-05-21 Derivados de (tio) carbamoil-ciclohexano como antagonistas del receptor d3/d2.
UAA200600942A UA84022C2 (ru) 2003-08-04 2004-05-21 Производные (тио)карбамоилциклогексана как антагонисты d3/d2 рецептора
EP04734301A EP1663996B1 (en) 2003-08-04 2004-05-21 (thio)carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
SI200431919T SI1663996T1 (sl) 2003-08-04 2004-05-21 Derivati (tio)karbamoil-cikloheksana kot antagonisti D3/D2 receptorja
AU2004261490A AU2004261490B2 (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
CA002532818A CA2532818C (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
PT04734301T PT1663996E (pt) 2003-08-04 2004-05-21 Derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2
RS20060041A RS52771B (en) 2003-08-04 2004-05-21 CARBAMOIL-CYCLOHEXANE DERIVATIVES (TIO) AS AN D3 / D2 RECEPTOR ANTAGONISTS
MEP-2008-849A ME00564B (me) 2003-08-04 2004-05-21 Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora
PCT/HU2004/000056 WO2005012266A1 (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
PL04734301T PL1663996T3 (pl) 2003-08-04 2004-05-21 Pochodne (tio)karbamoilocykloheksanu jako antagoniści receptorów D3/D2
KR1020067002364A KR100870284B1 (ko) 2003-08-04 2004-05-21 Ｄ３/ｄ２ 리셉터 길항물질로서의(티오)카르바모일-시클로헥산 유도체
ES04734301T ES2389840T3 (es) 2003-08-04 2004-05-21 Derivados de (tio)carbamoil-ciclohexano como antagonistas de receptores de D3/D2
BRPI0413283A BRPI0413283B8 (pt) 2003-08-04 2004-05-21 Composto derivado de (tio)carbamoil-ciclohexano, seu processo de preparação, amina, composição farmacêutica e uso do composto
JP2006522421A JP3999806B2 (ja) 2003-08-04 2004-05-21 Ｄ３／ｄ２受容体アンタゴニストとしての（チオ）カルバモイル−シクロヘキサン誘導体
CN2004800219507A CN1829703B (zh) 2003-08-04 2004-05-21 作为d3/d2受体拮抗剂的(硫代)氨基甲酰基-环己烷衍生物
DK04734301.7T DK1663996T3 (da) 2003-08-04 2004-05-21 (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister
NZ544999A NZ544999A (en) 2003-08-04 2004-05-21 (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
TW093115688A TWI327141B (en) 2003-08-04 2004-06-01 New cyclohexane derivatives having(thio)carbamoyl side chain
MYPI20042187A MY142760A (en) 2003-08-04 2004-06-07 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
IL172746A IL172746A (en) 2003-08-04 2005-12-21 History of (Theo) Carbamoyl – Cyclohexane as receptor antagonists d3 / d2
IS8199A IS2905B (is) 2003-08-04 2005-12-22 Afleiður (þíó) karbamóýl-sýklóhexans sem mótlyf D3/D2 viðtaka
TNP2005000328A TNSN05328A1 (en) 2003-08-04 2005-12-23 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
US11/337,275 US7737142B2 (en) 2003-08-04 2006-01-20 (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
ZA200601026A ZA200601026B (en) 2003-08-04 2006-02-03 (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
MA28855A MA28024A1 (fr) 2003-08-04 2006-03-03 Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
NO20061076A NO334973B1 (no) 2003-08-04 2006-03-06 (Tio)karbamoyl-sykloheksanderivater, fremgangsmåte for deres fremstilling, farmasøytiske preparater derav, deres anvendelse innen terapi og/eller forhindring av en tilstand som krever modulering av dopaminreseptorer.
HK07100087.7A HK1093494A1 (en) 2003-08-04 2007-01-04 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
US12/779,014 US20100240640A1 (en) 2003-08-04 2010-05-12 (THIO) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists
HRP20120715TT HRP20120715T1 (hr) 2003-08-04 2012-09-07 Derivati (tio)karbamoil-cikloheksana kao antagonisti d3/d2 receptora
CY20121100815T CY1113099T1 (el) 2003-08-04 2012-09-10 Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
LTPA2017027C LTC1663996I2 (lt) 2003-08-04 2017-08-24 (Tio)karbamoil-cikloheksano dariniai kaip D3/D2 receptorių antagonistai
NO2017051C NO2017051I2 (no) 2003-08-04 2017-10-09 Kariprazin, eventuelt i form av et salt
LU00039C LUC00039I2 (hu) 2003-08-04 2017-10-10
FR17C0008C FR17C0008I1 (fr) 2003-08-04 2017-10-10 Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
CY2017032C CY2017032I2 (el) 2003-08-04 2017-10-18 Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
HUS1700044C HUS1700044I1 (hu) 2003-08-04 2017-11-02 (Tio)karbamoil-ciklohexán származékok, mint D3/D2 receptor antagonisták
BE2017C045C BE2017C045I2 (hu) 2003-08-04 2017-11-14
NL300913C NL300913I2 (nl) 2003-08-04 2017-11-17 Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
HU0302451D0 HU0302451D0 (en) 2003-10-28
HUP0302451A2 true HUP0302451A2 (hu) 2005-05-30
HU227534B1 HU227534B1 (en) 2011-08-29

Family

ID=89981557

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUS1700044C HUS1700044I1 (hu) 2003-08-04 2017-11-02 (Tio)karbamoil-ciklohexán származékok, mint D3/D2 receptor antagonisták

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700044C HUS1700044I1 (hu) 2003-08-04 2017-11-02 (Tio)karbamoil-ciklohexán származékok, mint D3/D2 receptor antagonisták

Country Status (37)

Country Link
US (2) US7737142B2 (hu)
EP (1) EP1663996B1 (hu)
JP (1) JP3999806B2 (hu)
KR (1) KR100870284B1 (hu)
CN (1) CN1829703B (hu)
AU (1) AU2004261490B2 (hu)
BE (1) BE2017C045I2 (hu)
BR (1) BRPI0413283B8 (hu)
CA (1) CA2532818C (hu)
CY (2) CY1113099T1 (hu)
DK (1) DK1663996T3 (hu)
EA (1) EA009022B1 (hu)
ES (1) ES2389840T3 (hu)
FR (1) FR17C0008I1 (hu)
HK (1) HK1093494A1 (hu)
HR (1) HRP20120715T1 (hu)
HU (2) HU227534B1 (hu)
IL (1) IL172746A (hu)
IS (1) IS2905B (hu)
LT (1) LTC1663996I2 (hu)
LU (1) LUC00039I2 (hu)
MA (1) MA28024A1 (hu)
ME (1) ME00564B (hu)
MX (1) MXPA06001033A (hu)
MY (1) MY142760A (hu)
NL (1) NL300913I2 (hu)
NO (2) NO334973B1 (hu)
NZ (1) NZ544999A (hu)
PL (1) PL1663996T3 (hu)
PT (1) PT1663996E (hu)
RS (1) RS52771B (hu)
SI (1) SI1663996T1 (hu)
TN (1) TNSN05328A1 (hu)
TW (1) TWI327141B (hu)
UA (1) UA84022C2 (hu)
WO (1) WO2005012266A1 (hu)
ZA (1) ZA200601026B (hu)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070371A1 (en) 2008-12-18 2010-06-24 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
WO2010070370A1 (en) 2008-12-18 2010-06-24 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
WO2010070369A1 (en) 2008-12-17 2010-06-24 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
WO2011073705A1 (en) 2009-12-17 2011-06-23 Richter Gedeon Nyrt. Novel process for the preparation of piperazine compounds and hydrochloride salts thereof

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
CA2667511A1 (en) 2006-10-31 2008-05-08 F. Hoffmann-La Roche Ag Ether derivatives dual modulators of the 5-ht2a and d3 receptors
HUP0700269A2 (en) 2007-04-11 2009-04-28 Richter Gedeon Nyrt Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
CA2756796C (en) * 2007-05-11 2018-05-22 Forest Laboratories Holdings Limited Novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
WO2009020897A1 (en) * 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR101563383B1 (ko) * 2008-02-21 2015-10-26 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
MY156288A (en) * 2008-07-16 2016-01-29 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
CN103130737B (zh) * 2011-12-05 2015-12-02 江苏恒谊药业有限公司 环己烷胺类化合物及其作为抗精神分裂症药物的应用
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
EP2906221B1 (en) 2012-10-11 2019-05-15 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) * 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
CN105085345B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 含硝基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105085346B (zh) * 2015-08-14 2017-03-29 天津小新医药科技有限公司 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN111925304A (zh) * 2015-09-22 2020-11-13 江苏恩华药业股份有限公司 一种用于制备卡利拉嗪的化合物及其制备方法
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
WO2018021447A1 (ja) 2016-07-28 2018-02-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
CN107793350B (zh) * 2016-09-05 2021-06-04 上海医药工业研究院 芳乙基哌啶基衍生物及其治疗精神分裂症的应用
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
EP3744721A4 (en) 2018-01-26 2021-11-10 Shionogi & Co., Ltd CONDENSED CYCLIC COMPOUND WITH ANTAGONISM TO DOPAMINE D3 RECEPTOR
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
CN110872262A (zh) 2018-08-29 2020-03-10 上海科胜药物研发有限公司 一种卡利拉嗪的合成方法
CN110872270A (zh) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN110872269A (zh) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN111320594A (zh) * 2018-12-13 2020-06-23 江苏恩华药业股份有限公司 一种卡利拉嗪杂质及其制备工艺和用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
CN110372557B (zh) * 2019-08-06 2021-05-18 上海勋和医药科技有限公司 环己烷胺类d3/d2受体部分激动剂
MX2022004473A (es) 2019-10-29 2022-05-06 Shanghai Hansoh Biomedical Co Ltd Modificador de un derivado de anillo de cuatro miembros, metodo de preparacion y aplicacion del mismo.
KR20220119013A (ko) * 2019-11-05 2022-08-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도
HUP2100108A1 (hu) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására
AU2022266937A1 (en) 2021-04-28 2023-10-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023042081A1 (en) 2021-09-15 2023-03-23 Richter Gedeon Nyrt. PROCESS TO PRODUCE (1r,4r)-4-SUBSTITUTED CYCLOHEXANE-1-AMINES
HUP2200312A1 (hu) 2022-08-05 2024-02-28 Richter Gedeon Nyrt Kariprazin tartalmú szájban diszpergálódó tabletta
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
KR20060120715A (ko) 1998-03-31 2006-11-27 아카디아 파마슈티칼스 인코포레이티드 무스카린 수용체에 대해 활성을 갖는 화합물
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070369A1 (en) 2008-12-17 2010-06-24 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
WO2010070371A1 (en) 2008-12-18 2010-06-24 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
WO2010070370A1 (en) 2008-12-18 2010-06-24 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
US8569497B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
WO2011073705A1 (en) 2009-12-17 2011-06-23 Richter Gedeon Nyrt. Novel process for the preparation of piperazine compounds and hydrochloride salts thereof

Also Published As

Publication number Publication date
LTC1663996I2 (lt) 2018-05-25
US7737142B2 (en) 2010-06-15
BRPI0413283A (pt) 2006-10-10
CN1829703B (zh) 2011-06-08
JP2007501215A (ja) 2007-01-25
AU2004261490B2 (en) 2008-08-21
NL300913I2 (nl) 2017-12-20
TW200505874A (en) 2005-02-16
ES2389840T3 (es) 2012-11-02
WO2005012266A1 (en) 2005-02-10
IL172746A (en) 2016-02-29
US20060229297A1 (en) 2006-10-12
MA28024A1 (fr) 2006-07-03
NO2017051I2 (no) 2018-11-19
CY2017032I1 (el) 2018-02-14
TWI327141B (en) 2010-07-11
RS52771B (en) 2013-10-31
IS2905B (is) 2014-10-15
PT1663996E (pt) 2012-09-24
TNSN05328A1 (en) 2007-07-10
MXPA06001033A (es) 2006-04-24
EA009022B1 (ru) 2007-10-26
IL172746A0 (en) 2006-04-10
HU0302451D0 (en) 2003-10-28
US20100240640A1 (en) 2010-09-23
SI1663996T1 (sl) 2012-10-30
LUC00039I1 (hu) 2017-10-16
EA200600364A1 (ru) 2006-06-30
UA84022C2 (ru) 2008-09-10
MY142760A (en) 2010-12-31
CY2017032I2 (el) 2018-02-14
CN1829703A (zh) 2006-09-06
LTPA2017027I1 (lt) 2017-09-25
IS8199A (is) 2005-12-22
HRP20120715T1 (hr) 2012-09-30
KR20060058096A (ko) 2006-05-29
RS20060041A (en) 2009-11-10
CA2532818C (en) 2009-07-14
NO20061076L (no) 2006-03-06
NO334973B1 (no) 2014-08-11
DK1663996T3 (da) 2012-10-01
JP3999806B2 (ja) 2007-10-31
EP1663996B1 (en) 2012-06-20
NO2017051I1 (no) 2017-10-09
NZ544999A (en) 2009-07-31
PL1663996T3 (pl) 2012-11-30
LUC00039I2 (hu) 2017-12-20
EP1663996A1 (en) 2006-06-07
ME00564A (en) 2011-12-20
BE2017C045I2 (hu) 2023-08-09
KR100870284B1 (ko) 2008-11-25
BRPI0413283B1 (pt) 2021-10-05
AU2004261490A1 (en) 2005-02-10
NL300913I1 (hu) 2017-11-23
CY1113099T1 (el) 2016-04-13
HUS1700044I1 (hu) 2017-11-28
HU227534B1 (en) 2011-08-29
FR17C0008I1 (fr) 2018-12-07
BRPI0413283B8 (pt) 2021-10-05
HK1093494A1 (en) 2007-03-02
CA2532818A1 (en) 2005-02-10
ME00564B (me) 2011-12-20
ZA200601026B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
HUP0302451A2 (hu) (Tio)karbamoil-ciklohexán származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
HUP0400888A2 (hu) Helyettesített ciklohexán-1,4-diamin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
TW200639158A (en) New compounds with therapeutic effect
RS39704A (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
HUP0204245A2 (hu) Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1277736T3 (da) Hidtil ukendte bicykliske forbindelser
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
NO20032161L (no) Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamine D3-reseptor (antipsykotiske midler)
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0300693A2 (hu) Eljárás epotilon-analógok és -intermedierek előállítására
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
TW200716528A (en) Cyclopropanecarboxamide derivatives
TW200510441A (en) Novel compounds
HUP0400343A2 (hu) Ciklopropil-indol-származékok mint szelektív szerotonin-újrafelvétel inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL178350A0 (en) Vitamin d derivatives
TW200619212A (en) Morpholine derivatives
HUP0301811A2 (hu) Hipolipidémiás és hipokoleszterinémiás hatású szubsztituált pirrolszármazékok, azokat tartalmazó gyógyszerkészítmények, eljárás elżállításukra, köztitermékek és alkalmazásuk
HUP0201356A2 (hu) Ösztrogén agonisták/antagonisták alkalmazása depresszió kezelésére vagy a kognitív funkció romlásának megelőzésére alkalmas gyógyászati készítmény előállítására
AR038421A1 (es) Compuesto sulfonamida de 1,2,4,5-tetrahidrobenzo (d) azepina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
NZ545580A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
HUP9902199A1 (hu) Új nitronszármazékok, ezek előállítási eljárása és ezeket tartalmazó gyógyszerkészítmények
GB0412314D0 (en) Compounds
YU18404A (sh) Hemijska jedinjenja
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: RICHTER GEDEON NYRT., HU

Free format text: FORMER OWNER(S): RICHTER GEDEON VEGYESZETI GYAR RT., HU

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished